431 related articles for article (PubMed ID: 18027874)
1. Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome.
Krag A; Møller S; Henriksen JH; Holstein-Rathlou NH; Larsen FS; Bendtsen F
Hepatology; 2007 Dec; 46(6):1863-71. PubMed ID: 18027874
[TBL] [Abstract][Full Text] [Related]
2. Terlipressin in hepatorenal syndrome: Evidence for present indications.
Rajekar H; Chawla Y
J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():109-14. PubMed ID: 21199521
[TBL] [Abstract][Full Text] [Related]
3. Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1.
Boyer TD; Sanyal AJ; Wong F; Frederick RT; Lake JR; O'Leary JG; Ganger D; Jamil K; Pappas SC;
Gastroenterology; 2016 Jun; 150(7):1579-1589.e2. PubMed ID: 26896734
[TBL] [Abstract][Full Text] [Related]
4. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response.
Sharma P; Kumar A; Shrama BC; Sarin SK
Am J Gastroenterol; 2008 Jul; 103(7):1689-97. PubMed ID: 18557715
[TBL] [Abstract][Full Text] [Related]
5. Natriuretic response to the combination of atrial natriuretic peptide and terlipressin in patients with cirrhosis and refractory ascites.
Gadano A; Moreau R; Vachiery F; Soupison T; Yang S; Cailmail S; Sogni P; Hadengue A; Durand F; Valla D; Lebrec D
J Hepatol; 1997 Jun; 26(6):1229-34. PubMed ID: 9210608
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome.
Krag A; Borup T; Møller S; Bendtsen F
Adv Ther; 2008 Nov; 25(11):1105-40. PubMed ID: 19018483
[TBL] [Abstract][Full Text] [Related]
7. Terlipressin and gelafundin: safe therapy of hepatorenal syndrome.
Saner F; Kavuk I; Lang H; Biglarnia R; Frühauf NR; Schäfers RF; Malagó M; Broelsch CE
Eur J Med Res; 2004 Feb; 9(2):78-82. PubMed ID: 15090293
[TBL] [Abstract][Full Text] [Related]
8. Effects of a single terlipressin administration on cardiac function and perfusion in cirrhosis.
Krag A; Bendtsen F; Mortensen C; Henriksen JH; Møller S
Eur J Gastroenterol Hepatol; 2010 Sep; 22(9):1085-92. PubMed ID: 20453655
[TBL] [Abstract][Full Text] [Related]
9. Terlipressin versus albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomized study.
Singh V; Kumar R; Nain CK; Singh B; Sharma AK
J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 2):303-7. PubMed ID: 16460491
[TBL] [Abstract][Full Text] [Related]
10. Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study.
Ghosh S; Choudhary NS; Sharma AK; Singh B; Kumar P; Agarwal R; Sharma N; Bhalla A; Chawla YK; Singh V
Liver Int; 2013 Sep; 33(8):1187-93. PubMed ID: 23601499
[TBL] [Abstract][Full Text] [Related]
11. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial.
Solanki P; Chawla A; Garg R; Gupta R; Jain M; Sarin SK
J Gastroenterol Hepatol; 2003 Feb; 18(2):152-6. PubMed ID: 12542598
[TBL] [Abstract][Full Text] [Related]
12. Effects of terlipressin on the aquaretic system: evidence of antidiuretic effects.
Krag A; Bendtsen F; Pedersen EB; Holstein-Rathlou NH; Møller S
Am J Physiol Renal Physiol; 2008 Nov; 295(5):F1295-300. PubMed ID: 18753292
[TBL] [Abstract][Full Text] [Related]
13. Dobutamine reverses the cardio-suppressive effects of terlipressin without improving renal function in cirrhosis and ascites: a randomized controlled trial.
Israelsen M; Dahl EK; Madsen BS; Wiese S; Bendtsen F; Møller S; Fialla AD; Jensen BL; Krag A
Am J Physiol Gastrointest Liver Physiol; 2020 Feb; 318(2):G313-G321. PubMed ID: 31841026
[TBL] [Abstract][Full Text] [Related]
14. The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond.
Moreau R; Lebrec D
Hepatology; 2006 Mar; 43(3):385-94. PubMed ID: 16496352
[TBL] [Abstract][Full Text] [Related]
15. The use of terlipressin in cirrhotic patients with refractory ascites and normal renal function: a multicentric study.
Fimiani B; Guardia DD; Puoti C; D'Adamo G; Cioffi O; Pagano A; Tagliamonte MR; Izzi A
Eur J Intern Med; 2011 Dec; 22(6):587-90. PubMed ID: 22075285
[TBL] [Abstract][Full Text] [Related]
16. Effects of terlipressin on systemic, hepatic and renal hemodynamics in patients with cirrhosis.
Narahara Y; Kanazawa H; Taki Y; Kimura Y; Atsukawa M; Katakura T; Kidokoro H; Harimoto H; Fukuda T; Matsushita Y; Nakatsuka K; Sakamoto C
J Gastroenterol Hepatol; 2009 Nov; 24(11):1791-7. PubMed ID: 19686420
[TBL] [Abstract][Full Text] [Related]
17. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome.
Neri S; Pulvirenti D; Malaguarnera M; Cosimo BM; Bertino G; Ignaccolo L; Siringo S; Castellino P
Dig Dis Sci; 2008 Mar; 53(3):830-5. PubMed ID: 17939047
[TBL] [Abstract][Full Text] [Related]
18. Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study.
Mulkay JP; Louis H; Donckier V; Bourgeois N; Adler M; Deviere J; Le Moine O
Acta Gastroenterol Belg; 2001; 64(1):15-9. PubMed ID: 11322061
[TBL] [Abstract][Full Text] [Related]
19. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.
Martín-Llahí M; Pépin MN; Guevara M; Díaz F; Torre A; Monescillo A; Soriano G; Terra C; Fábrega E; Arroyo V; Rodés J; Ginès P;
Gastroenterology; 2008 May; 134(5):1352-9. PubMed ID: 18471512
[TBL] [Abstract][Full Text] [Related]
20. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites.
Angeli P; Volpin R; Piovan D; Bortoluzzi A; Craighero R; Bottaro S; Finucci GF; Casiglia E; Sticca A; De Toni R; Pavan L; Gatta A
Hepatology; 1998 Oct; 28(4):937-43. PubMed ID: 9755229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
